Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fox Chase Chemical Diversity Center Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This application is assigned to 1 distinct examiner and is being processed within 1 distinct art unit. This indicates a focused prosecution profile with no current overlap between multiple active matters.
DEKARSKE, MADELINE MCGUIRE serves as the busiest examiner for the portfolio, managing 1 pending office action. This action accounts for the total of 1 pending office action for the company. Because the workload is limited to 1 distinct examiner and 1 distinct art unit, the applicant can dedicate resources to addressing the specific requirements of this individual examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546285 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | DEKARSKE, MADELINE MCGUIRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18546285 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | DEKARSKE, MADELINE MCGUIRE | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18546285 | SMALL MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF ALS AND RELATED DISORDERS | DEKARSKE, MADELINE MCGUIRE | 1622 | §103§112 | Non-Final OA | — | Pending | Aug 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFox Chase Chemical Diversity Center Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Madeline Mcguire Dekarske has the most, with 1 of Fox Chase Chemical Diversity Center Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
